SANUWAVE Health Inc.
Amgen mourns death of founder George Rathmann | Personnel Moves
Bovie swings to 2011 black | Earnings Roundup
Sanuwave takes its dermaPace foot ulcer treatment back to trials
Regenerative medicine firm Sanuwave Health (OTC:SNWV) will run another clinical trial of its dermaPace foot ulcer treatment, after the FDA determined that its initial pre-market approval bid failed to meet its primary endpoint.
New trials may take up to 2 years before the company re-submits its device for FDA review, according to a press release.
Sorin’s 2011 sales stay flat, profits soar | Earnings Roundup
Sorin Group (BIT:SRN) reported flat sales but strong profit growth for 2011, saying it raised earnings by 48.3% and revealing that the cardiac rhythm management slump has made its way across the pond.
The Italian medical device maker posted net income of €58.0 million (~$75.2 million) on sales of €743.4 million (~$963.4 million) for the year ended Dec. 31, 2011. That compares with profits of €39.1 million (~$50.7 million) on sales of €745.8 million (~$966.5 million) during 2010.
FDA wants another dermaPACE study from Sanuwave
The FDA wants Sanuwave Health (OTC:SNWV) to run another clinical trial of its dermaPACE diabetic foot ulcer treatment, after a review of the company’s pre-market approval bid found that the initial trial failed to meet its primary endpoint.
Zoll shares spike 23 percent on record 2011 sales and earnings | Earnings Roundup
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night’s $35.98 close.
The company’s 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.
Early-stage angel investment rises, but early-stage VC funding falls
Venture capital investment is on the wane, but angel investment is increasing, according to a pair of recent reports.
The University of New Hampshire’s Center for Venture Research reports that angel investment rose nearly 5 percent during the first and second quarters, to $8.9 billion, compared with the same period last year. Health care and medical device firms took the lion’s share of the angel cash (25 percent, according to the report), which usually comes from the proverbial "high net worth individuals" or in early-stage funding rounds.
DJO Global’s executive vice president resigns | Personnel Moves
Medical device maker DJO Global, Inc. announced that its executive vice president of U.S. commercial operations, Andrew Holman, will leave the company “to pursue other opportunities.”
Newly minted DJO president & CEO Mike Mogul will assume responsibility for the San Diego, Calif.-based company’s U.S. commercial activities.
Intrinsic Therapeutics puts a new man in charge | Personnel Moves
Intrinsic Therapeutics named Wright Medical (NSQD:WMGI) veteran Cary Hagan as its new President & CEO. Greg Lambrect, founder of Intrinsic will stay on as executive director.
"Cary’s proven success in bringing new technologies to the global market makes him an ideal choice to lead Intrinsic’s next stage of growth as we expand our international clinical and commercial activity," said Lambrecht in prepared remarks.
SANUWAVE appoints MedTech veteran Ron Sparks to board of directors
ANUWAVE Appoints Medical Technology Veteran Ron Sparks to Board of Directors
Appointment of Executive with Successful Track Record in Wound Care and Medical Devices
ALPHARETTA, Ga.–(BUSINESS WIRE)–SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that Ron Sparks, age 56, a 34-year veteran of the medical device industry, has joined the Company’s Board of Directors.